CS
NRIX icon

Candriam SCA’s Nurix Therapeutics NRIX Stock Holding History

Candriam SCA’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.16M Sell
377,902
-156,357
-29% -$2.66M 0.04% 296
2026
Q1 		$8.28M Hold
534,259
– – 0.04% 308
2025
Q4 		$10.1M Buy
534,259
+271,875
+104% +$3.91M 0.05% 267
2025
Q3 		$2.42M Hold
262,384
– – 0.01% 474
2025
Q2 		$2.99M Sell
262,384
-326,547
-55% -$3.53M 0.02% 431
2025
Q1 		$7M Sell
588,931
-45,695
-7% -$764K 0.04% 276
2024
Q4 		$12M Sell
634,626
-427,333
-40% -$9.8M 0.07% 238
2024
Q3 		$23.9M Sell
1,061,959
-102,287
-9% -$2.32M 0.14% 152
2024
Q2 		$24.3M Buy
1,164,246
+272,136
+31% +$4.24M 0.15% 142
2024
Q1 		$13.1M Sell
892,110
-26,000
-3% -$280K 0.08% 224
2023
Q4 		$9.48M Sell
918,110
-50,000
-5% -$343K 0.07% 258
2023
Q3 		$7.61M Sell
968,110
-51,712
-5% -$472K 0.05% 260
2023
Q2 		$10.2M Buy
1,019,822
+119,734
+13% +$1.22M 0.07% 244
2023
Q1 		$7.36M Buy
900,088
+49,513
+6% +$516K 0.05% 300
2022
Q4 		$9.34M Buy
850,575
+25,000
+3% +$302K 0.06% 284
2022
Q3 		$10.8M Sell
825,575
-13,800
-2% -$218K 0.08% 255
2022
Q2 		$10.6M Buy
839,375
+74,269
+10% +$842K 0.09% 216
2022
Q1 		$10.7M Sell
765,106
-28,997
-4% -$515K 0.07% 245
2021
Q4 		$23M Buy
794,103
+239,107
+43% +$7.25M 0.15% 159
2021
Q3 		$16.6M Buy
554,996
+47,693
+9% +$1.47M 0.11% 201
2021
Q2 		$13.5M Buy
507,303
+507,290
+3,902,231% +$14.9M 0.09% 242
2021
Q1 		$0 Buy
+13
New +$492 ﹤0.01% 815

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Candriam SCA's NRIX Position: Q2 2026 in Review

Candriam SCA reduced its Nurix Therapeutics (NRIX) stake by 29% in Q2 2026, selling an estimated $2.66M and leaving 377,902 shares worth $9.16M. The position accounts for 0.04% of the portfolio, ranked #296.

Candriam SCA first reported a position in NRIX in Q1 2021 and has held it in 22 quarters since. The position peaked at $24.3M in Q2 2024. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Candriam SCA held 377,902 shares of Nurix Therapeutics worth $9.16M as of Q2 2026.
  • Candriam SCA sold 156,357 Nurix Therapeutics shares in Q2 2026, an estimated $2.66M.
  • Nurix Therapeutics made up 0.04% of Candriam SCA's portfolio in Q2 2026, its #296 holding.
  • Candriam SCA first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Candriam SCA's Nurix Therapeutics position peaked at $24.3M in Q2 2024.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.